MXPA04000411A - Tiazolidinonas arilo sustituidas y uso de las mismas. - Google Patents

Tiazolidinonas arilo sustituidas y uso de las mismas.

Info

Publication number
MXPA04000411A
MXPA04000411A MXPA04000411A MXPA04000411A MXPA04000411A MX PA04000411 A MXPA04000411 A MX PA04000411A MX PA04000411 A MXPA04000411 A MX PA04000411A MX PA04000411 A MXPA04000411 A MX PA04000411A MX PA04000411 A MXPA04000411 A MX PA04000411A
Authority
MX
Mexico
Prior art keywords
treatment
prevention
formula
aryl substituted
aryl
Prior art date
Application number
MXPA04000411A
Other languages
English (en)
Inventor
Sun Qun
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MXPA04000411A publication Critical patent/MXPA04000411A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/06—1,3-Thiazines; Hydrogenated 1,3-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Esta invencion se refiere a tiazolidinonas arilo sustituidas de formula I (I) (ver formula) o una sal farmaceuticamente aceptable, o solvato de las mismas, en donde n es un entero de 1 a 2; R1 se selecciona del grupo que consiste de: (I) donde Y es alquileno y R3 y R4 son iguales o diferentes y se seleccionan de hidrogeno, alquilo o arilo, o R3 y R4 juntos forman una cadena de alquileno que tiene 4 a 5 atomos de carbono opcionalmente interrumpidos por un nitrogeno u oxigeno; (ii) piridilalquilo; y (iii) piperidin-4-ilo, fenilo opcionalmente sustituido; 2,2-difeniletenilo; furanilo; carbozolilo. La invencion esta dirigida tambien al uso de compuestos de formula (I) para el tratamiento de dano neuronal despues de isquemia global y focal, para el tratamiento o prevencion de condiciones neurodegenerativas tales como esclerosis lateral amiotrofica (ALS), y para el tratamiento, prevencion o mejora de dolor tanto agudo como cronico, como farmacos contra el trastorno maniaco depresivo como anestesicos locales, como antiarrltmicos y para el tratamiento o prevencion de neuropatia diabetica.
MXPA04000411A 2001-07-16 2002-07-16 Tiazolidinonas arilo sustituidas y uso de las mismas. MXPA04000411A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30509901P 2001-07-16 2001-07-16
PCT/US2002/022367 WO2003008398A1 (en) 2001-07-16 2002-07-16 Aryl substituted thiazolidinones and the use thereof

Publications (1)

Publication Number Publication Date
MXPA04000411A true MXPA04000411A (es) 2004-03-18

Family

ID=23179332

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000411A MXPA04000411A (es) 2001-07-16 2002-07-16 Tiazolidinonas arilo sustituidas y uso de las mismas.

Country Status (7)

Country Link
US (2) US7169782B2 (es)
EP (1) EP1417187A1 (es)
JP (1) JP2004538285A (es)
CA (1) CA2453633A1 (es)
IL (1) IL159765A0 (es)
MX (1) MXPA04000411A (es)
WO (1) WO2003008398A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159765A0 (en) * 2001-07-16 2004-06-20 Euro Celtique Sa Aryl substituted thiazolidinone derivatives and pharmaceutical compositions containing the same
PT1483247E (pt) * 2002-03-13 2009-08-18 Euro Celtique Sa Pirimidinas substituídas por arilo e a sua utilização
AU2003257033A1 (en) * 2002-07-31 2004-02-16 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
US20050227974A9 (en) * 2002-08-01 2005-10-13 Euro-Celtique S.A. Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
US20040152696A1 (en) * 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
GB2396613A (en) * 2002-08-23 2004-06-30 Ionix Pharmaceuticals Ltd Five-membered heterocyclic compounds in the treatment of chronic and acute pain
CN102413828A (zh) * 2009-05-12 2012-04-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的噻唑烷-4-酮和[1,3]-噻嗪烷-4-酮化合物
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
CA2811479A1 (en) 2010-09-17 2012-03-22 Purdue Pharma L.P. Pyridine compounds and the uses thereof
US9045435B2 (en) 2010-10-05 2015-06-02 Purdue Pharma, L.P. Quinazoline compounds as sodium channel blockers
AU2011346751A1 (en) 2010-12-22 2013-05-02 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
JP5941546B2 (ja) 2011-09-02 2016-06-29 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリミジン
US9181185B2 (en) 2011-10-31 2015-11-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
US9388137B2 (en) 2011-10-31 2016-07-12 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
CN103130793B (zh) * 2011-11-30 2016-09-21 中国人民解放军军事医学科学院毒物药物研究所 3-(1-芳基哌啶-4-基)-2-芳基噻唑啉-4-酮类化合物、其制备方法及用途
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
EP2935257B1 (en) 2012-12-20 2018-02-07 Purdue Pharma LP Cyclic sulfonamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
ES2680246T3 (es) 2013-03-04 2018-09-05 Purdue Pharma Lp Pirimidincarboxamidas como bloqueantes de canal de sodio
EP2968307A4 (en) 2013-03-15 2017-01-04 Purdue Pharma LP Carboxamide derivatives and use thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9884865B2 (en) 2013-08-26 2018-02-06 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
US9745287B2 (en) 2013-12-20 2017-08-29 Purdue Pharma L.P. Pyrimidines and use thereof
JP6337124B2 (ja) 2013-12-23 2018-06-06 パーデュー、ファーマ、リミテッド、パートナーシップ インダゾール及びその使用
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
EP3097078B1 (en) 2014-01-24 2022-05-25 Purdue Pharma LP Pyridines and pyrimidines and use thereof
US10738026B2 (en) 2014-02-12 2020-08-11 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
CA2948144A1 (en) 2014-05-06 2015-11-12 Purdue Pharma L.P. Benzomorphan analogs and use thereof
MA40170A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés hétérocycliques de morphinan et leur utilisation
EP3154972A4 (en) 2014-06-13 2017-11-22 Purdue Pharma L.P. Azamophinan derivatives and use thereof
CN107613965A (zh) 2015-02-19 2018-01-19 普渡制药公司 用于减少胃排空的方法和组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US40025A (en) * 1863-09-22 Improvement in wheel-vehicles
US6947A (en) * 1849-12-11 Self-acting car-coupling
US55088A (en) * 1866-05-29 Improved buckle
US3309377A (en) * 1964-10-19 1967-03-14 Sterling Drug Inc 3-[(2-oxazolidinone-3-yl)-alkyl]-4-thiazolidinones and their preparation
US3377355A (en) * 1967-06-30 1968-04-09 Sterling Drug Inc 4-thiazolidones and oxide derivatives thereof
CH548411A (de) 1971-12-06 1974-04-30 Ciba Geigy Ag Verfahren zur herstellung von neuen 1,1-dioxothiazolidin4-onen.
JPS5764685A (en) * 1980-10-09 1982-04-19 Kureha Chem Ind Co Ltd 2-(substituted phenyl)-1,3-thiazin-4(3,5,6h)-one and remedy for peptic ulcer containing said compound as active component
US4992455A (en) 1987-05-22 1991-02-12 Sumitomo Pharmaceuticals Company, Limited Thiazolidin-4-one derivatives useful for treating diseases caused by platelet activating factor
ES2052675T3 (es) * 1987-11-20 1994-07-16 Hoechst Roussel Pharma 3-(4-piperazinil-sustituido en 1)butil)-4-tiazolidinonas, un procedimiento para su preparacion y su uso como medicamentos.
US5061720A (en) * 1989-09-13 1991-10-29 A. H. Robins Company, Inc. Substituted-4-thiazolidinone derivatives
CZ14294A3 (en) 1991-07-23 1994-07-13 Schering Corp Substituted beta-lactam compounds usable as hypocholesterol pharmaceutical preparations and process for preparing thereof
KR100262419B1 (ko) 1993-06-23 2000-09-01 나가야마 오사무 허혈성 질환에 유용한 벤젠 유도체
CA2157348A1 (en) 1994-09-01 1996-03-02 Aventis Pharmaceuticals Inc. 3-¬4-(1-substituted-4-piperazinyl)butyl|-4-thiazolidinone and related compounds
CA2334258A1 (en) 1998-06-05 1999-12-09 Icagen, Inc. Potassium channel inhibitors
WO2000057877A1 (en) * 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
AU4249700A (en) 1999-04-19 2000-11-02 Sumitomo Pharmaceuticals Company, Limited Hydroxamic acid derivative
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
CN1321112C (zh) * 2000-03-24 2007-06-13 欧洲凯尔特股份有限公司 作为钠通道阻滞剂的芳基取代的吡唑、三唑和四唑化合物
MXPA02009619A (es) * 2000-03-31 2004-07-30 Eruro Celtique S A Aminopiridinas y su uso como anticonvulsivos y bloqueadores del canal de sodio.
IL159765A0 (en) * 2001-07-16 2004-06-20 Euro Celtique Sa Aryl substituted thiazolidinone derivatives and pharmaceutical compositions containing the same
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) * 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
PT1483247E (pt) * 2002-03-13 2009-08-18 Euro Celtique Sa Pirimidinas substituídas por arilo e a sua utilização

Also Published As

Publication number Publication date
EP1417187A1 (en) 2004-05-12
WO2003008398A1 (en) 2003-01-30
JP2004538285A (ja) 2004-12-24
US20040176364A1 (en) 2004-09-09
US20030109521A1 (en) 2003-06-12
IL159765A0 (en) 2004-06-20
US7169782B2 (en) 2007-01-30
CA2453633A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
MXPA04000411A (es) Tiazolidinonas arilo sustituidas y uso de las mismas.
EA200601847A1 (ru) Замещённые метиларил- или гетероариламидные соединения
TW200519088A (en) Aryl or heteroaryl amide compounds
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
MXPA04002171A (es) Piridicarboxamidas aril sustituidas y su uso como bloqueadores del canal de sodio.
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
MXPA04002172A (es) Derivados de piridina 2-(4-fenoxi)heterociclicos substituidos, compuestos relacionados como bloqueadores de canal de sodio para tratamiento de dano neurologico y neurodegenerativo.
MXPA05000812A (es) Bencimidazoles aril sustituidos y su uso como bloqueadores del canal de sodio.
TW200635585A (en) Monocyclic substituted methanones
ATE312100T1 (de) Chinuclidin-verbindungen und medikamente die diese als aktive wirkstoffe enthalten
NO20073371L (no) TNF-alfa-produksjonsinhibitorer
DE60301345D1 (de) Stabilisierte askorbinsäurederivate
TW200611687A (en) Pharmaceutical compositions used for immunosuppressant
TW200420558A (en) Amide compounds
PT1280809E (pt) Derivados antitumorais de ecteinascidina
TW200727893A (en) Methods for treating sexual dysfunction
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
PT1044186E (pt) Composto 2-benzilamino-2-fenil-acetamida substituidos
MXPA05008706A (es) 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas.
SG146681A1 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
GB0125127D0 (en) Compounds
MY136065A (en) Prodrugs to nmda receptor ligands
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
DK1049672T3 (da) Azetidincarboxamid-derivater til behandling af CNS-lidelser
IT1313623B1 (it) Uso di carbonati organici come solventi per il lavaggio di superficimetalliche